1. Carisma's Chief Scientific Officer will speak at a major conference. 2. The company focuses on macrophage engineering for innovative therapies. 3. Carisma aims to transform treatment paradigms in multiple diseases.
Participation in a notable conference may enhance visibility and investor interest, similar to past events that spurred stock price increases.
The company's engagement in significant industry events often correlates with investor sentiment and market activity.
The upcoming presentation may lead to immediate interest but not long-term changes without further announcements.
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.
Shveta Dighe [email protected]
Julia Stern (763) 350-5223 [email protected]
SOURCE Carisma Therapeutics Inc.